Lonza Group AG (LZAGF)
| Market Cap | 56.53B +21.3% |
| Revenue (ttm) | 8.50B +25.6% |
| Net Income | -136.14M |
| EPS | -1.92 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 32.50 |
| Dividend | 6.40 (0.79%) |
| Ex-Dividend Date | May 12, 2026 |
| Volume | 102 |
| Open | 825.00 |
| Previous Close | 832.45 |
| Day's Range | 784.61 - 828.11 |
| 52-Week Range | 565.14 - 841.45 |
| Beta | 0.81 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 11, 2026 |
About Lonza Group AG
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanc... [Read more]
News
Lonza price target raised to CHF 820 from CHF 760 at RBC Capital
RBC Capital raised the firm’s price target on Lonza (LZAGY) to CHF 820 from CHF 760 and keeps an Outperform rating on the shares.
Lonza to buy five US sites from Merck KGaA
Contract drug manufacturer Lonza said on Tuesday it would buy five US manufacturing sites from Merck KGaA, more than doubling its footprint in the country and expanding its capabilities to produce ad...
Lonza Group To Buy Merck's CDMO Business
(RTTNews) - Lonza Group (LONN.SW, LZAGF.PK) said on Tuesday that it has inked a deal to acquire five contract development and manufacturing organization, CDMO, sites in the U.S. from Merck KGaA (MRCG....
Lonza Group AG Transcript: M&A announcement
The acquisition adds five U.S. CDMO sites, ~1,100 employees and capabilities across bioconjugates, payload-linkers, viral vectors and non-viral delivery. Closing is expected in mid-2027; FY 2028 sales are projected at ~CHF 250m, with profitability expected to improve through the mid-2030s.
Lonza Group AG Press release: M&A announcement
Lonza Group AG issued a press release on November 3, 2026, disclosing material business information to investors.
Lonza Group AG Slides: M&A announcement
Lonza Group AG has posted slides in relation to its latest quarterly earnings report, which was published on November 3, 2026.
Lonza Group AG Transcript: CMD 2026
The upgraded model targets 10%-13% organic growth, high-30%s midterm CORE EBITDA margins and ROIC of 2x-3x WACC. Capacity investments, integrated services and operational improvements support growth across biologics and other modalities.
Lonza Group AG Slides: FY 2026
Lonza Group AG has posted slides in relation to its FY 2026 quarterly earnings report, which was published on October 14, 2026.
Lonza Group AG Press release: FY 2026
Lonza Group AG issued a press release on October 14, 2026, disclosing material business information to investors.
Lonza Sees Maturing Projects Driving Profitability Higher Over Medium Term
The company said it upgraded its midterm ambitions, reflecting its narrowed focus on the contract drug-manufacturing business following the planned sale of its capsules-and-health-ingredients unit.
Lonza Group AG Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Strong demand from pharma and biotech supports robust growth across business segments, with Advanced Synthesis and specialized modalities outperforming. Regulatory and tariff impacts remain limited, while disciplined CapEx and M&A strategies underpin sustainable margin and cash flow improvements.
Lonza price target raised to CHF 697 from CHF 656 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Lonza (LZAGY) to CHF 697 from CHF 656 and keeps a Buy rating on the shares.
Lonza price target raised to CHF 760 from CHF 720 at RBC Capital
RBC Capital analyst Charles Weston raised the firm’s price target on Lonza (LZAGY) to CHF 760 from CHF 720 and keeps an Outperform rating on the shares. Published first on…
Lonza Group AG Earnings Call Transcript: H1 2026
H1 2026 saw robust 16% CER sales growth, margin expansion to 34.8%, and improved free cash flow, driven by strong performance across all business platforms and disciplined execution. The company completed its transformation to a pure-play CDMO, upgraded its margin outlook, and reaffirmed double-digit sales growth guidance.
Lonza Group AG Quarterly report: H1 2026
Lonza Group AG has published its H1 2026 quarterly earnings report on July 22, 2026.
Lonza Group AG Slides: H1 2026
Lonza Group AG has posted slides in relation to its H1 2026 quarterly earnings report, which was published on July 22, 2026.
Lonza Group AG Earnings release: H1 2026
Lonza Group AG released its H1 2026 earnings on July 22, 2026, summarizing the period's financial results.
Lonza raises full-year core profit margin guidance
Switzerland's Lonza , the world's largest contract drug manufacturer, raised the full-year target for its core profit margin to between 33% and 34% on Wednesday, citing strong operational execu...
Lonza price target raised to CHF 640 from CHF 590 at HSBC
HSBC raised the firm’s price target on Lonza (LZAGY) to CHF 640 from CHF 590 and keeps a Buy rating on the shares. In a sector note on Healthcare, HSBC…
Lonza price target raised to CHF 720 from CHF 670 at RBC Capital
RBC Capital analyst Charles Weston raised the firm’s price target on Lonza (LZAGY) to CHF 720 from CHF 670 and keeps an Outperform rating on the shares. Published first on…
Lonza price target lowered to CHF 590 from CHF 700 at HSBC
HSBC lowered the firm’s price target on Lonza (LZAGY) to CHF 590 from CHF 700 and keeps a Buy rating on the shares. The firm says market expectations on life…
Lonza price target lowered to CHF 656 from CHF 695 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Lonza (LZAGY) to CHF 656 from CHF 695 and keeps a Buy rating on the shares.
Lonza Group AG Earnings Call Transcript: Q1 2026
Q1 saw strong performance across all CDMO platforms, with 2026 sales growth guided at 11%-12% CER and CORE EBITDA margin above 32%. Divestment of CHI and robust CapEx progress support a pure-play CDMO focus, while proactive risk management and healthy demand underpin the outlook.
Lonza Group AG Earnings release: Q1 2026
Lonza Group AG released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Simulations Plus enters funded research collaboration with Lonza, FDA
Simulations Plus (SLP) announced a funded research collaboration with Lonza Group (LZAGY) and the U.S. Food and Drug Administration to develop and validate a mechanistic, predictive framework for asse...